B. Ordonez-Perez | Authors

UNIVERSITY OF UTAH DIVISION OF UROLOGY

""30 N 1900 E, RM 3B420""

Articles

In Vivo Purging With Rituximab Prior to Stem Cell Collection Is Associated With Persistent Molecular Evidence of t(14;18) That Often Disappears Post-Transplant in Patients With Follicular Lymphoma

March 01, 2000

We previously reported that “in vivo purging” with rituximab (Rituxan) during stem-cell collection is safe and does not adversely affect engraftment. We now report on our transplant experience with rituximab. From June 1998 to December